1-phenethyl-4-piperidinecarbonitrile | 23793-56-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-phenethyl-4-piperidinecarbonitrile
• 英文别名: 4-cyano-1-(2-phenylethyl)piperidine；1-(2-Phenylethyl)-isonipecotonitril；1-(2-phenylethyl)piperidine-4-carbonitrile
• CAS: 23793-56-8
• 化学式: C₁₄H₁₈N₂
• mdl: MFCD11936884
• 分子量: 214.31
• InChiKey: QDNKANVPPGGTHL-UHFFFAOYSA-N

物化性质

• 沸点：
  352.8±35.0 °C(Predicted)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,4-二氯溴苯 、 1-phenethyl-4-piperidinecarbonitrile 在 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 硫酸 、 甲苯 为溶剂， 生成 (3,4-Dichlorophenyl)[1-(2-phenylethyl)-4-piperidinyl]-methanone HCl
  参考文献：
  名称：

  N-aralkyl piperidine methanol derivatives and the uses thereof

  摘要：

  这项发明涉及一类具有重要生化和药理特性的新化合物。更具体地说，这项发明涉及N-芳基哌啶甲醇衍生物，这些衍生物是5HT.sub.2受体位点上血清素结合的有效和选择性抑制剂，并涉及其制备和使用的方法。

  公开号：

  US04783471A1

文献信息

• N-Aralkyl piperidinemethanol derivatives
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0208235A1

  公开（公告）日：1987-01-14

  This invention relates to a new class of compounds having important biochemical and pharmacological properties. More particularly, this invention relates to N-aralkyl piperidinemethanol derivatives which are potent and selective inhibitors of the binding of serotonin at the 5HT2 receptor site, and to the processes for their preparation and use.

  本发明涉及一种具有重要生物化学和药理学性质的新类化合物。更具体地说，本发明涉及N-芳基烷基哌啶甲醇衍生物，它们是5HT2受体位点血清素结合的有效选择性抑制剂，并涉及其制备和使用的过程。
• Novel chemical compounds
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US04912117A1

  公开（公告）日：1990-03-27

  This invention relates to a new class of compounds having important biochemical and pharmacological properties. More particularly, this invention relates to N-aralkyl piperidinemethanol derivatives which are potent and selective inhibitors of the binding of serotonin at the 5HT.sub.2 receptor site, and to the processes for their preparation and use.

  本发明涉及一类具有重要生物化学和药理学特性的新化合物。更具体地说，本发明涉及N-芳基烷基哌啶甲醇衍生物，这些衍生物是5HT.sub.2受体位点血清素结合的有效选择性抑制剂，并涉及其制备和使用的过程。
• N-aralkyl-piperidine-methanol derivatives
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05169096A1

  公开（公告）日：1992-12-08

  This invention relates to a new class of compounds having important biochemical and pharmacological properties. More particularly, this invention relates to N-aralkyl piperidinemethanol derivatives which are potent and selective inhibitors of the binding of serotonin at the 5HT.sub.2 receptor site, and to the processes for their preparation and use.

  本发明涉及一类具有重要生化和药理特性的新化合物。更具体地说，本发明涉及N-芳基烷基哌啶甲醇衍生物，它们是5HT.sub.2受体位点血清素结合的有效选择性抑制剂，以及它们的制备和应用过程。
• Novel chemical compounds for the prophylactic treatment of migraine
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05021428A1

  公开（公告）日：1991-06-04

  The invention relates to a new class of compounds having important biochemical and pharmacological properties. More particularly, this invention relates to N-aralkyl piperidinemethanol derivatives which are potent and selective inhibitors of the binding of serotonin at the 5HT.sub.2 receptor site, and to the processes for their preparation and use.

  本发明涉及一类具有重要生化和药理特性的新化合物。更具体地说，本发明涉及N-芳基烷基哌啶甲醇衍生物，它们是5HT.sub.2受体位点上血清素结合的有效和选择性抑制剂，以及它们的制备和使用方法。
• Tertiary carbinamines by addition of organocerium reagents to nitriles and ketimines
  作者：Engelbert Ciganek

  DOI：10.1021/jo00042a037

  日期：1992.7

  Organocerium reagents, prepared by reaction of aromatic and primary and secondary alkyllithium reagents with anhydrous cerium chloride, add to nitriles twice to give tertiary carbinamines in often excellent yields. Addition of n-BuCeCl2 to acetophenone is about 4 times faster than addition to benzonitrile. Only 1,2-diaddition is observed in the reaction of MeCeCl2 with cinnamonitrile. The species formed in the double addition of organocerium reagents to nitriles are sufficiently basic to generate a benzyne intermediate by abstraction of an aromatic proton and nucleophilic enough to undergo an intramolecular Chichibabin reaction. Reaction of N-unsubstituted ketimines or their lithium salts with organocerium reagents permits the synthesis of tertiary carbinamines with three different groups on the tertiary carbon center.